Colleen Young, Connect Director | @colleenyoung | Jan 7, 2020
Hi @burrkay, I have just been reading about this new treatment protocol: Enhertu (trastuzumab deruxtecan) (DS-8201) for the treatment of patients with HER2-positive metastatic breast cancer. I understand that it received accelerated FDA approval due to the promising study results
Thank you @burrkay and @colleenyoung for posting the question and sharing this new treatment information. Due to recent scans that indicate my cancer is unfortunately and likely progressing, I'm beginning to research new treatment options with my oncologist. My genetic testing indicated HR+ Low Grade Metastatic Ovarian Cancer which is rare and more difficult to find studies and treatments suited directly to this disease. However I've been on 2 breast cancer drugs which was successful until recently due to the HR+ component found often in breast cancer treatments. Any new treatment ideas in these areas are very much appreciated. I'll continue my research, but please do share! Again, I very much appreciate the information.
Create an account to connect with other patients and caregivers like you. Ask questions, get answers, and give and get support. Also follow blogs from Mayo Clinic experts.
Connect
MayoClinic.org
Hi @burrkay, I have just been reading about this new treatment protocol: Enhertu (trastuzumab deruxtecan) (DS-8201) for the treatment of patients with HER2-positive metastatic breast cancer. I understand that it received accelerated FDA approval due to the promising study results
– Trastuzumab Deruxtecan Receives Accelerated Approval by FDA for HER2+ Breast Cancer https://www.targetedonc.com/news/trastuzumab-deruxtecan-receives-accelerated-approval-by-fda-for-her2-breast-cancer
Do you know someone who is starting this treatment?
Thank you @burrkay and @colleenyoung for posting the question and sharing this new treatment information. Due to recent scans that indicate my cancer is unfortunately and likely progressing, I'm beginning to research new treatment options with my oncologist. My genetic testing indicated HR+ Low Grade Metastatic Ovarian Cancer which is rare and more difficult to find studies and treatments suited directly to this disease. However I've been on 2 breast cancer drugs which was successful until recently due to the HR+ component found often in breast cancer treatments. Any new treatment ideas in these areas are very much appreciated. I'll continue my research, but please do share! Again, I very much appreciate the information.